
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>f_Sofinnova Capital IV_2017Q4 FS-PTF (Audit)_007.pdf</i></p>
<p style="font-size: small; color: grey;"><i>Sofinnova Capital IV</i></p>
<p>basis of the proceeds received and receivable. There is no significant change in the value of the investment over the year as the price of the transaction was taken into account as of December 31, 2016. Under the by-laws of the Fund Sofinnova Partners was not authorized to proceed with this transaction. The unitholders have been asked to vote and confirmed their agreement to proceed with the transaction.</p>
<p>Addex Pharmaceuticals - SWX Swiss Exchange [ADXN] is valued at market price of CHF2.29 per share as of December 31, 2017 with a €75k increase in value over the year.</p>
<p>Our overall position in Addex since inception can be analysed as follows as of December 31, 2017:</p>

<table>
	<tr>
		<th>Unrealized</th>
		<th></th>
		<th>% inv.</th>
		<th>Amount invested</th>
		<th>Valuation</th>
		<th>Unrealized gain/Loss</th>
		<th>MoC</th>
	</tr>
	<tr>
		<td>311,667</td>
		<td>Common stock</td>
		<td></td>
		<td>6,609,975</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td></td>
		<td></td>
		<td>38.6%</td>
		<td>6,609,975</td>
		<td>610,300</td>
		<td>(5,999,675)</td>
		<td>0.1</td>
	</tr>
	<tr>
		<td>Realized</td>
		<td></td>
		<td>% inv.</td>
		<td>Amount invested</td>
		<td>Proceeds</td>
		<td>Realized gain/Loss</td>
		<td></td>
	</tr>
	<tr>
		<td colspan="2">494,981 Common stock</td>
		<td>61.4%</td>
		<td>10,497,781</td>
		<td>1,372,947</td>
		<td>(9,124,833)</td>
		<td>0.1</td>
	</tr>
	<tr>
		<td>806,648</td>
		<td>Common stock</td>
		<td>100%</td>
		<td>17,107,756</td>
		<td>1,983,247</td>
		<td>(15,124,508)</td>
		<td>0.1</td>
	</tr>
</table>
<h2>1.3.3 Gross internal rate of return and gross multiple</h2>
<p>As of December 31, 2017, the Gross IRR (on the basis of a periodic monthly IRR) and the Gross multiples were as follows:</p>

<table>
	<tr>
		<th>Gross Multiple as of December 31, 2017</th>
		<th>Life Sciences</th>
		<th>Technology</th>
		<th>Overall Fund</th>
	</tr>
	<tr>
		<td>Realized Investments (incl. milestones &amp; escrow)</td>
		<td>1.86</td>
		<td>0.90</td>
		<td>1.44</td>
	</tr>
	<tr>
		<td>Residual portfolio</td>
		<td>0.09</td>
		<td>0.95</td>
		<td>0.54</td>
	</tr>
	<tr>
		<td>Overall portfolio (Realized &amp; Unrealized)</td>
		<td>1.80</td>
		<td>0.90</td>
		<td>1.40</td>
	</tr>
</table>

<table>
	<tr>
		<th>Gross IRR as of December 31, 2017</th>
		<th>Life Sciences</th>
		<th>Technology</th>
		<th>Overall Fund</th>
	</tr>
	<tr>
		<td>Realized Investments (incl. milestones &amp; escrow)</td>
		<td>14.2%</td>
		<td>(1.9%)</td>
		<td>7.9%</td>
	</tr>
	<tr>
		<td>Residual portfolio</td>
		<td>(17.1%)</td>
		<td>(0.5%)</td>
		<td>(4.8%)</td>
	</tr>
	<tr>
		<td>Overall portfolio (Realized &amp; Unrealized)</td>
		<td>13.4%</td>
		<td>(1.7%)</td>
		<td>7.1%</td>
	</tr>
</table>
<h2>1.4 Fund performance</h2>
<h2>1.4.1 Capital calls</h2>
<p>As of December 31, 2017, 100% of the Fund&#x27;s capital, or €330 million, has been paid up. The last tranche of 5% was paid up in May 2008. A breakdown of the capital contributions since creation of the Fund is shown in paragraph 4.1.3.3.</p>
<h2>1.4.2 Distributions</h2>
<p>There were no distributions during the year.</p>
<p>Overall, the Fund&#x27;s cumulative distributions to investors as of December 31, 2017 amounted to €376.5 million representing 114.7% of investors&#x27; committed and contributed capital of €328.3 million.</p>
<p style="font-size: small; color: grey;"><i>Confidential</i></p>
<p style="font-size: small; color: grey;"><i>6</i></p>

</body>
</html>
